Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients
Open Access
- 22 June 2016
- journal article
- research article
- Published by Springer Nature in Drugs in R&D
- Vol. 16 (3) , 255-261
Abstract
Objectives This study aimed to investigate changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics after a meal tolerance test (MTT) during treatment with dapagliflozin among obese type 2 diabetes mellitus (T2DM) patients. Methods T2DM patients with hemoglobin A1c (HbA1c) levels >6.5 % and body mass index (BMI) >25 kg/m2 were treated with dapagliflozin 5 mg/day for at least 12 weeks. HbA1c, body weight, ketone bodies, adiponectin, plasminogen activator inhibitor-1 (PAI-1), and C-reactive protein (CRP) were measured before and after treatment with dapagliflozin. A subset of patients underwent an MTT. Results Of 27 participating patients (mean age 47.9 years; 17 males), five were drug-naive and 22 were treated with other antidiabetic agents, including insulin and glucagon-like peptide-1 (GLP-1) receptor agonists. Following treatment with dapagliflozin, HbA1c levels significantly improved (7.44 ± 0.56 to 6.70 ± 0.0.57 %; p < 0.01), body weight significantly decreased (90.9 ± 16.5 to 87.1 ± 15.9 kg; p < 0.01), ketone bodies increased, adiponectin significantly increased, and high-sensitivity CRP tended to decrease. During the MTT, blood glucose ΔAUC2 significantly decreased, glucagon ΔAUC2 increased, and immunoreactive insulin (IRI) did not change in 11 of 27 patients. Conclusion Although ketone bodies increased significantly, adiponectin increased and high-sensivity CRP decreased significantly. These findings suggest that sodium-glucose cotransporter-2 (SGLT2) inhibitors may potentially improve adipocyte function in treating obese T2DM patients.Keywords
This publication has 22 references indexed in Scilit:
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 InhibitionDiabetes Care, 2015
- 6. Glycemic TargetsDiabetes Care, 2014
- Effects of a community-based weight loss intervention on adipose tissue circulating factorsDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2014
- A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention ProgramActa Diabetologica, 2014
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJournal of Clinical Investigation, 2014
- The Clinical Efficacy and Safety of Sodium Glucose Cotransporter‐2 Inhibitors in Adults with Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.2011
- Enhanced expressions of sodium–glucose cotransporters in the kidneys of diabetic Zucker ratsDiabetes Research and Clinical Practice, 2009
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985